Tags : Imbruvica

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they […]Read More

Janssen’s Imbruvica (ibrutinib) Receives European Commission Approval for Chronic Lymphocytic

Shots: The approval is based on P-III iLLUMINATE (PCYC-1130) and P-III iNNOVATE (PCYC-1127) study assessing Imbruvica + obinutuzumab vs chlorambucil + obinutuzumab and Imbruvica + rituximab vs rituximab + PBO in patients with previously untreated CLL and r/r WM respectively Collective results: improvement in PFS with the use of ibrutinib-based therapy vs SOC providing CT […]Read More

AbbVie’s Imbruvica (ibrutinib) + Gazyva (obinutuzumab) Receives FDA’s Approval, First

Shots: The combinational approval is based P-III iLLUMANTE (PCYC-1130) study results assessing Imbruvica + Gazyva vs chlorambucil + Gazyva in patients with 1L+ Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) aged ≥ 65 years The P-III iLLUMANTE study resulted in 77% reduction in risk of progression or death and has also shown 85% reduction in progression […]Read More

AbbVie Receives US FDA Approval for Imbruvica plus Rituximab for

 Shots: Combination of Imbruvica (ibrutinib) & Rituxan (rituximab) approval is the first and only CT free combination treatment in all line of therapies  This approval is based on P-III iNNOVATE (PCYC-1127) trial (N=150) assessing (Imbruvica+ Rituxan vs Rituxan alone) where PFS (82% vs 28%) with mPFS as 26.5mos and reduction in disease progression or death […]Read More